NCT01476722

Brief Summary

The purpose of this study was to evaluate the efficacy of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens wearers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Jun 2011

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 18, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 22, 2011

Completed
12 months until next milestone

Results Posted

Study results publicly available

November 19, 2012

Completed
Last Updated

November 19, 2012

Status Verified

November 1, 2012

Enrollment Period

4 months

First QC Date

November 18, 2011

Results QC Date

October 19, 2012

Last Update Submit

November 16, 2012

Conditions

Keywords

Silicone HydrogelSoft Contact LensesMulti-Purpose Solution

Outcome Measures

Primary Outcomes (4)

  • Corneal Fluorescein Staining Type at Baseline

    Corneal staining type was assessed by the investigator for each of 5 regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. Corneal staining type was recorded on a 5-point scale for each region: 0-none; 1-micropunctate; 2-macropunctate; 3-coalesced macropunctate; 4-patch (\>/= 1mm). The five regions were summed, for a maximum score of 20. A lower score represents a more desirable outcome.

    Day 0 (Baseline)

  • Corneal Fluorescein Staining Type at Day 30

    Corneal staining type was assessed by the investigator for each of 5 regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. Corneal staining type was recorded on a 5-point scale for each region: 0-none; 1-micropunctate; 2-macropunctate; 3-coalesced macropunctate; 4-patch (\>/= 1mm). The five regions were summed, for a maximum score of 20. A lower score represents a more desirable outcome.

    Day 30

  • Corneal Fluorescein Staining Area at Baseline

    Corneal staining was assessed by the investigator for each of five regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. The area (extent) of corneal staining for each of the five areas was estimated \[i.e., 0% (no staining in the region) to 100% (staining covers entire region)\], for a maximum score of 100% per eye. A lower score represents a more desirable outcome.

    Day 0 (Baseline)

  • Corneal Fluorescein Staining Area at Day 30

    Corneal staining was assessed by the investigator for each of five regions of the cornea, i.e., four quadrants plus central. The investigator instilled fluorescein dye and examined the cornea with a slit lamp, i.e., biomicroscope and a yellow filter. The area (extent) of corneal staining for each of the five areas was estimated \[i.e., 0% (no staining in the region) to 100% (staining covers entire region)\], for a maximum score of 100% per eye. A lower score represents a more desirable outcome.

    Day 30

Study Arms (1)

OPTI-FREE PureMoist

EXPERIMENTAL

OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days

Device: OPTI-FREE PureMoist multipurpose disinfecting solution

Interventions

FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days

OPTI-FREE PureMoist

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Wear silicone hydrogel or traditional soft contact lenses on a daily wear basis, (a minimum of 8 hours per day) for at least one month prior to Visit 1;
  • Habitual use of a multi-purpose solution containing PHMB for at least 30 days prior to Visit 1;
  • Vision correctable to 20/30 (Snellen) or better in each eye at distance with pre-study lenses at Visit 1;
  • Read, sign, and date IRB-approved informed consent and privacy document;
  • Be generally healthy and have normal ocular health;
  • Willing to follow the study procedures and visit schedule;

You may not qualify if:

  • Wear lenses on an extended wear basis during the study;
  • Known sensitivity or intolerance to PHMB, POLYQUAD, or ALDOX preserved lens care products;
  • Monocular subject;
  • Requirestoric or multifocal contact lenses;
  • Use of additional lens care products other than a PHMB multi-purpose solution such as daily or enzyme cleaners within the one week prior to Visit 1;
  • Use of topical ocular over-the-counter (OTC) or prescribed topical ocular medications, with the exception of rewetting drops, within 7 days prior to Visit 1;
  • Any abnormal ocular condition observed during the Visit 1 Slit-lamp examination;
  • Ocular surgery within the 12 months prior to Visit 1;
  • Use of any systemic medication which has known or expected ocular or systemic side effects at Visit 1, that in the clinical judgment of the investigator, could affect the subject's participation in this study;
  • Any systemic disease at Visit 1 that may affect the eye or be exacerabated by use of contact lenses or contact lens solutions or which could prevent subjects from wearing their lenses at least 8 hours per day;
  • Participation in any clinical study within 30 days of Visit 1;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Contact Alcon Call Center for Trial Locations

Fort Worth, Texas, 76314, United States

Location

Results Point of Contact

Title
Jami Kern, Ph.D.
Organization
alcon Blobal Medical Affairs

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2011

First Posted

November 22, 2011

Study Start

June 1, 2011

Primary Completion

October 1, 2011

Study Completion

October 1, 2011

Last Updated

November 19, 2012

Results First Posted

November 19, 2012

Record last verified: 2012-11

Locations